Nucleic acids encoding antibodies against PD-1
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 3, 2012
Grant Date -
Feb 4, 2010
app pub date -
Mar 16, 2009
filing date -
Dec 23, 2002
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
This disclosure provides antibodies and antigen-binding fragments that can act as agonists and/or antagonists of PD-1 (Programmed Death 1), thereby modulating immune responses in general, and those mediated by TcR and CD28, in particular. The disclosed compositions and methods may be used for example, in treating autoimmune diseases, inflammatory disorders, allergies, transplant rejection, cancer, and other immune system disorders.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully